Sensors,
Journal Year:
2024,
Volume and Issue:
24(21), P. 6988 - 6988
Published: Oct. 30, 2024
In
biological
micromanipulation,
cell
penetration
is
a
typical
procedure
that
precedes
injection
or
oocyte
enucleation.
During
this
procedure,
cells
usually
undergo
significant
deformation,
which
leads
to
damage.
paper,
we
focus
on
modeling
and
evaluating
the
process
reduce
deformation
stress,
thereby
reducing
Initially,
finite
element
model
(FEM)
established
simulate
process.
The
effectiveness
of
then
verified
through
visual
detection
comparison
with
experimental
data.
Next,
various
mechanical
responses
are
analyzed,
considering
influence
parameters,
such
as
radius
shape
micropipettes,
material
properties,
size
cells.
Finally,
relationship
between
intracellular
stress
depth
obtained.
evaluation
results
will
be
applied
develop
optimized
operation
plans,
enhancing
efficiency
safety
International Journal of Pharmaceutics,
Journal Year:
2024,
Volume and Issue:
658, P. 124192 - 124192
Published: May 3, 2024
Ocular
delivery
is
the
most
challenging
aspect
in
field
of
pharmaceutical
research.
The
major
hurdle
for
controlled
drugs
to
eye
includes
physiological
static
barriers
such
as
complex
layers
cornea,
sclera
and
retina
which
restrict
drug
from
permeating
into
anterior
posterior
segments
eye.
Recent
years
have
witnessed
inventions
conventional
nanocarrier
shown
considerable
enhancement
delivering
small
large
molecules
across
dynamic
challenges
associated
with
systems
include
limited
contact
time
inadequate
ocular
bioavailability
resulting
solution
drainage,
tear
turnover,
dilution
or
lacrimation.
To
this
end,
various
bioactive-based
nanosized
carriers
including
liposomes,
ethosomes,
niosomes,
dendrimer,
nanogel,
nanofibers,
lenses,
nanoprobes,
selenium
nanobells,
nanosponge,
polymeric
micelles,
silver
nanoparticles,
gold
nanoparticles
among
others
been
developed
circumvent
limitations
dosage
forms.
These
nanocarriers
achieve
enhanced
permeation
retention
prolong
release
tissue
due
their
better
adherence.
surface
charge
size
(10–1000
nm)
are
important
key
factors
overcome
barriers.
Various
deliver
active
therapeutic
timolol
maleate,
ampicillin,
natamycin,
voriconazole,
cyclosporine
A,
dexamethasone,
moxifloxacin,
fluconazole
treatment
diseases.
Taken
together,
a
nutshell,
book
chapter
provides
comprehensive
perspective
on
numerous
facets
special
focus
bioactive
nanocarrier-based
approaches,
difficulties
constraints
involved
fabrication
nanocarriers.
This
also
detailed
invention
applications
ophthalmic
therapeutics.
Journal of Nanobiotechnology,
Journal Year:
2025,
Volume and Issue:
23(1)
Published: Feb. 25, 2025
The
human
retina
is
a
fragile
and
sophisticated
light-sensitive
tissue
in
the
central
nervous
system.
Unhealthy
retinas
can
cause
irreversible
visual
deterioration
permanent
vision
loss.
Effective
therapeutic
strategies
are
restricted
to
treatment
or
reversal
of
these
conditions.
In
recent
years,
nanoscience
nanotechnology
have
revolutionized
targeted
management
retinal
diseases.
Pharmaceuticals,
theranostics,
regenerative
medicine,
gene
therapy,
prostheses
indispensable
for
interventions
been
significantly
advanced
by
nanomedical
innovations.
Hence,
this
review
presents
novel
insights
into
use
versatile
nanomaterial-based
nanocomposites
frontier
applications,
including
non-invasive
drug
delivery,
theranostic
contrast
agents,
nanoagents,
stem
cell-based
optogenetics
prostheses,
which
mainly
reported
within
last
5
years.
Furthermore,
progress,
potential
challenges,
future
perspectives
field
highlighted
discussed
detail,
may
shed
light
on
clinical
translations
ultimately,
benefit
patients
with
disorders.
Advanced Science,
Journal Year:
2024,
Volume and Issue:
11(25)
Published: April 6, 2024
Abstract
Corneal
neovascularization
(CNV)
is
a
common
clinical
finding
seen
in
range
of
eye
diseases.
Current
therapeutic
approaches
to
treat
corneal
angiogenesis,
which
vascular
endothelial
growth
factor
(VEGF)
A
plays
central
role,
can
cause
variety
adverse
side
effects.
The
technology
Clustered
Regularly
Interspaced
Short
Palindromic
Repeats
(CRISPR)/Cas9
edit
VEGFA
gene
suppress
its
expression.
CRISPR
offers
novel
opportunity
CNV.
This
study
shows
that
depletion
with
CRISPR/Cas9
system
inhibits
proliferation,
migration,
and
tube
formation
human
umbilical
vein
cells
(HUVECs)
vitro.
Importantly,
subconjunctival
injection
this
dual
AAV‐SpCas9/sgRNA‐
demonstrated
blocks
suture‐induced
expression
VEGFA,
CD31,
α‐smooth
muscle
actin
as
well
mice.
has
established
strong
foundation
for
the
treatment
via
editing
approach
first
time.
Advanced Science,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 30, 2025
Abstract
The
advent
of
biomacromolecules
antagonizing
vascular
endothelial
growth
factor
(VEGF)
has
revolutionized
the
treatment
neovascular
age‐related
macular
degeneration
(nAMD).
However,
frequent
intravitreal
injections
these
impose
an
enormous
burden
on
patients
and
create
a
massive
workload
for
healthcare
providers.
This
causes
to
abandon
therapy,
ultimately
leading
progressive
irreversible
vision
loss.
In
order
address
this
unmet
clinical
need,
noninvasive
nAMD
is
developed.
An
optimized
cell‐penetrating
peptide
derivative,
bxy
Penetratin
(bxyWP),
used
non‐covalently
complex
with
anti‐VEGF
protein
aflibercept
(AFL)
via
reversible
hydrophobic
interaction.
interaction
crucial
AFL
delivery,
neither
impairing
affinity
pathological
VEGF,
nor
being
interfered
by
endogenous
proteins
in
tear
fluids.
AFL/bxyWP
eye
drops
exhibit
prolonged
retention
excellent
absorption
into
posterior
ocular
segment
following
topical
administration,
significant
drug
distribution
retina
choroid.
laser‐induced
choroidal
neovascularization
model
cynomolgus
monkeys,
efficiently
reduce
lesion
size
leakage
comparable
conventional
injection
AFL.
These
results
suggest
that
are
feasible
self‐administered
retinal
diseases
potentially
become
substitute
injections.
Aggregate,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 9, 2025
ABSTRACT
Corneal
neovascularization
(CNV)
is
a
debilitating
ocular
surface
disease
that
severely
compromises
visual
function
and
carries
significant
risk
of
vision
loss.
Despite
its
clinical
impact,
the
development
effective
safe
pharmacological
treatments
for
CNV
remains
an
unmet
medical
need.
The
pathogenesis
largely
driven
by
inflammation
excessive
oxidative
stress.
In
this
study,
we
introduce
novel
nanotherapeutic
strategy
utilizing
vanadium
carbide
quantum
dots
(V
2
C
QDs)
with
intrinsic
nanozyme
properties,
co‐encapsulated
plasmid
encoding
interleukin‐10
(IL‐10)
within
biomimetic
metal‐organic
framework
(MOF)
treatment
CNV.
To
enhance
targeting
biocompatibility,
nanoparticles
(NPs)
are
further
coated
mesenchymal
stem
cell
(MSC)‐derived
membrane
vesicles
(CMVs),
yielding
final
nanomedicine
designated
as
MOF‐V
C‐Plasmid@CMVs
(MVPC).
vitro
studies
demonstrate
MVPC
NPs
effectively
scavenge
reactive
oxygen
species
(ROS)
induced
tert
‐butyl
hydroperoxide
(tBOOH),
mitigating
Moreover,
successful
delivery
expression
IL‐10
in
RAW264.7
cells
result
elevated
secretion,
showcasing
robust
anti‐inflammatory
activity.
CMV
coating
facilitates
targeted
delivery,
enabling
efficient
accumulation
region
following
topical
administration
via
eye
drops.
vivo
experiments
model
rats
reveal
nanotherapeutics
significantly
suppress
without
inducing
adverse
effects.
Collectively,
study
provides
proof
concept
multifunctional
platform
CNV,
offering
promising
clinically
translatable
approach
challenging
disease.
